Identification of subgroups and development of prognostic risk models along the glycolysis-cholesterol synthesis axis in lung adenocarcinoma

被引:1
作者
Jiang, Jiuzhou [1 ]
Qian, Bao [2 ]
Guo, Yangjie [2 ]
He, Zhengfu [1 ]
机构
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Med Coll, Dept Thorac Surg, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sch Med, Hangzhou, Peoples R China
关键词
Glycolysis; Cholesterol; XGBoost; SHAP; CANCER; MACHINE; METABOLISM; HALLMARKS;
D O I
10.1038/s41598-024-64602-7
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Lung cancer is one of the most dangerous malignant tumors affecting human health. Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Both glycolytic and cholesterogenic pathways play critical roles in metabolic adaptation to cancer. A dataset of 585 LUAD samples was downloaded from The Cancer Genome Atlas database. We obtained co-expressed glycolysis and cholesterogenesis genes by selecting and clustering genes from Molecular Signatures Database v7.5. We compared the prognosis of different subtypes and identified differentially expressed genes between subtypes. Predictive outcome events were modeled using machine learning, and the top 9 most important prognostic genes were selected by Shapley additive explanation analysis. A risk score model was built based on multivariate Cox analysis. LUAD patients were categorized into four metabolic subgroups: cholesterogenic, glycolytic, quiescent, and mixed. The worst prognosis was the mixed subtype. The prognostic model had great predictive performance in the test set. Patients with LUAD were effectively typed by glycolytic and cholesterogenic genes and were identified as having the worst prognosis in the glycolytic and cholesterogenic enriched gene groups. The prognostic model can provide an essential basis for clinicians to predict clinical outcomes for patients. The model was robust on the training and test datasets and had a great predictive performance.
引用
收藏
页数:13
相关论文
共 47 条
[1]  
Al-Barakati Hussam, 2022, Methods Mol Biol, V2499, P155, DOI 10.1007/978-1-0716-2317-6_8
[2]   DEVIANT ENERGETIC METABOLISM OF GLYCOLYTIC CANCER-CELLS [J].
BAGGETTO, LG .
BIOCHIMIE, 1992, 74 (11) :959-974
[3]   Next-Generation Machine Learning for Biological Networks [J].
Camacho, Diogo M. ;
Collins, Katherine M. ;
Powers, Rani K. ;
Costello, James C. ;
Collins, James J. .
CELL, 2018, 173 (07) :1581-1592
[4]   KRT6A Promotes Lung Cancer Cell Growth and Invasion Through MYC-Regulated Pentose Phosphate Pathway [J].
Che, Di ;
Wang, Mingshuo ;
Sun, Juan ;
Li, Bo ;
Xu, Tao ;
Lu, Yuxiong ;
Pan, Haiyan ;
Lu, Zhaoliang ;
Gu, Xiaoqiong .
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
[5]   Identification of differentially expressed genes in lung adenocarcinoma cells using single-cell RNA sequencing not detected using traditional RNA sequencing and microarray [J].
Chen, Zhencong ;
Zhao, Mengnan ;
Li, Ming ;
Sui, Qihai ;
Bian, Yunyi ;
Liang, Jiaqi ;
Hu, Zhengyang ;
Zheng, Yuansheng ;
Lu, Tao ;
Huang, Yiwei ;
Zhan, Cheng ;
Jiang, Wei ;
Wang, Qun ;
Tan, Lijie .
LABORATORY INVESTIGATION, 2020, 100 (10) :1318-1329
[6]   A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism [J].
Cui, Jiujie ;
Quan, Ming ;
Xie, Dacheng ;
Gao, Yong ;
Guha, Sushovan ;
Fallon, Michael B. ;
Chen, Jingde ;
Xie, Keping .
ONCOGENE, 2020, 39 (05) :1140-1151
[7]   Machine Learning in Medicine [J].
Deo, Rahul C. .
CIRCULATION, 2015, 132 (20) :1920-1930
[8]   Lipidomes of lung cancer and tumour-free lung tissues reveal distinct molecular signatures for cancer differentiation, age, inflammation, and pulmonary emphysema [J].
Eggers, Lars F. ;
Mueller, Julia ;
Marella, Chakravarthy ;
Scholz, Verena ;
Watz, Henrik ;
Kugler, Christian ;
Rabe, Klaus F. ;
Goldmann, Torsten ;
Schwudke, Dominik .
SCIENTIFIC REPORTS, 2017, 7
[9]   Amino Acid Oncometabolism and Immunomodulation of the Tumor Microenvironment in Lung Cancer [J].
Fahrmann, Johannes F. ;
Vykoukal, Jody V. ;
Ostrin, Edwin J. .
FRONTIERS IN ONCOLOGY, 2020, 10
[10]  
Gridelli C, 2015, NAT REV DIS PRIMERS, V1, DOI [10.1038/nrdp.2015.9, 10.1038/nrdp.2015.48]